



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1633  
Balseg  
**PATENT**

In re Application of:

Havenga et al.

Serial No.: 09/348,354

Filed: July 7, 1999

For: CHIMERIC ADENOVIRUSES

Examiner: G. Lee

Group Art Unit: 1633

Attorney Docket No.: 4123US

RECEIVED  
JAN 30 2001 #12B  
2-13-0  
P.7.  
TECH CENTER 1600/2900

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail (under 37 C.F.R. § 1.8(a)) on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

January 24, 2001  
Date of Deposit

*Lynette Eliason*  
Signature of registered practitioner or other person having reasonable basis to expect mailing to occur on date of deposit shown pursuant to 37 C.F.R. § 1.8(a)(1)(ii)

*Lynette Eliason*  
Typed/printed name of person whose signature is contained above

**RECEIVED**

FEB 13 2001

TECH CENTER 1600/2900

Amendment

Commissioner for Patents

Washington, D.C. 20231

Sir:

Responsive to the Office Action mailed 24 October 2000, please amend the referenced application as follows:

1-23-0001 438-354 0000701 1994-5304

C: 001208  
08 001203

129.00 00  
108.00 00

IN THE CLAIMS:

1. (Twice Amended) A chimeric adenovirus comprising:

B'  
at least a part of a fiber protein of a first adenovirus serotype[ providing], said at least a part of a fiber protein adapted to provide the chimeric [virus] adenovirus with a desired [host range] tropism to a plurality of target cells in a host; and

at least a part of a penton or hexon protein from a second adenovirus serotype, the second adenovirus serotype having a lower relative tropism to the plurality of target cells than that of the chimeric virus, the second adenovirus serotype having [that is] less [antigenic] antigenicity in a